Neurology biomarker firm C2N Diagnostics is accelerating its test development efforts with the aim of commercializing protein markers for the early detection of Alzheimer's as well as for use as primary endpoints in Phase III clinical trials of therapies for the disease.
NEW YORK (GenomeWeb News) — Exosome Diagnostics said today that it has entered into a collaboration agreement with Eli Lilly for biomarker discovery and validation using Exosome's EXO50 nucleic acid extraction kit.
NEW YORK (GenomeWeb News) – Qiagen said after the close of the market on Wednesday it has entered into an agreement with Eli Lilly to develop companion diagnostics for the drug firm's investigational and approved medicines across all therapeutic areas.
Qiagen said this week that GE Healthcare subsidiary Clarient will offer Qiagen's Therascreen KRAS RGQ PCR kit as a companion diagnostic to guide the use of Erbitux (cetuximab) as a treatment in patients with metastatic colorectal cancer.
NEW YORK (GenomeWeb News) – Agilent subsidiary Dako has entered into a "master framework agreement" with Eli Lilly to advance a companion diagnostic that gauges best responders for an undisclosed oncology treatment the drug maker is developing.
Researchers at the Washington University School of Medicine have picked two Alzheimer's drugs under development at Roche and Eli Lilly to take through a clinical trial that will test how well these agents prevent the disease in those genetically predisposed to get it.